Search

Background: In addition to adequate nutrition and balance of nutrients in the pregnant mother's diet, maternal weight gain during pregnancy has a major impact on maternal health and fetal well-being. The purpose of this study was to compare pre-gestational BMI and gestational weight gain on GDM according to the new definition of GDM. Materials and Methods: This descriptive cross-sectional study was carried out on 18 to 35 years old pregnant women with no underlying disease using convenience sampling method In the first months of pregnancy, women's height, weight and blood pressure as well as FBS were measured.The second assessment was done in the 24th-28th weeks of gestation using repeated measurements of weight, blood pressure, and gestational diabetes screening test (GCT). The third evaluation was conducted at the end of pregnancy to measure mother and infant weight.The data was analyzed by SPSS, version 16, t-test and Mann-Whitney test. Results: In this study, 600pregnant women were evaluated.Mean BMI befor pregnancy in the women with GDM was significantly higher than in the women without the above-mentioned problems(P=0.0001). The mean weight gained during pregnancy in the women with these symptoms was significantly higher than that in the women without the above –mentioned problems(P=0.039)(P=0.0001). Compared to pre-pregnancy BMI, weight gain during pregnancy had a higher with GDM(0.278 vs 0.077). Conclusion: Pre-pregnancy BMI in comparison with weight gain during pregnancy, had a higher correlation with GDM and macrosomia

Background : Graft versus host disease (GVHD) is among major complications of allogeneic hematopoietic stem cells transplantation, and also is an important factor affecting the outcome of transplantation. An increased incidence of GVHD has been suggested following allogeneic peripheral blood stem cells (PBSC) transplantation, however, how this affects survival is not yet well clear. In this study, our aim was to assess the impact of acute GVHD (aGVHD) and chronic GVHD (cGVHD) on overall survival (OS), disease-free survival (DFS) and relapse following non-T-cell depleted HLA-identical sibling peripheral blood stem cells transplantation (PBSCT). Materials and Methods: Data of 78 patients, including 40 patients with acute myeloid leukemia (AML) and 38 patients with acute lymphoblastic leukemia (ALL), undergoing non-T-cell depleted HLA-identical sibling allogeneic PBSCT,were analyzed. All patients were received a uniform myeloablative conditioning regimen and prophylaxis for GVHD. We studied the incidence of aGVHD and cGVHD and their effects on survival and relapse in these patients. Results: The overall incidence of aGVHD and chronic GVHD was 82.5% and 42.5% in the AML patients and 84.2% and 26.3% in the ALL patients. The occurrence of aGVHD had no effect on OS, DFS and relapse in AML and ALL patients receiving transplants. Although incidence of 2-year OS and DFS were significantly higher in the AML Patients with cGVHD compared to patients without cGVHD (P=0.024 and P=0.033, respectively), this difference was not due to the low incidence of relapse. Conclusion: These data indicate that the occurrence of cGVHD is an important predictor of outcome of non-T-cell depleted HLA-identical sibling allogeneic PBSCT, in those AML patients who develope cGVHD have a high chance of survival.